MedElevator
Войти в исследования Health affairs scholar · 2026
Socioeconomic value of adult respiratory vaccination in the United States: a benefit-cost analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Theakston Claud, Hu Tianyan, Brassel Simon, Vietri Jeffrey, Mendes Diana, Napier Matthew, Tunnicliffe Ellie, Yehoshua Alon, Farkouh Raymond, Steuten Lotte
Аннотация
BACKGROUND: Respiratory infections, including pneumococcal disease (PD), respiratory syncytial virus (RSV), influenza, and COVID-19, impose substantial health and economic burdens on adults in the United States. Although vaccines are available, coverage remains suboptimal.
METHODS: We conducted a societal-perspective benefit-cost analysis of adult PD, RSV, influenza, and COVID-19 vaccination programs. Four disease models estimated averted morbidity, mortality, and productivity losses. We evaluated current CDC recommendations and scenarios of varying eligibility and coverage. A complementary analysis estimated the net present value of 1 year's vaccination activity.
RESULTS: Under current age-based recommendations, vaccination prevents over 182 000 deaths and 2.5 million hospitalizations within 15 years. Society values these outcomes at 5-12 times the cost of delivering the programs. Including at-risk adults averts an additional 13 600 deaths. Restricting eligibility or coverage could increase vaccine-preventable hospitalizations by over 1 million, increasing healthcare costs by almost $50 billion; expanding eligibility and increasing coverage to 75% substantially improves societal welfare and could additionally avert over 100 000 deaths. One year's vaccination activity prevents ∼300 000 hospitalizations, and ∼18 500 deaths, generating $6-$12 in societal value per $1 spent.
CONCLUSIONS: Adult respiratory vaccination programs generate considerable societal returns. Increasing coverage and sustaining clear, evidence-based recommendations can unlock further health and economic gains.
METHODS: We conducted a societal-perspective benefit-cost analysis of adult PD, RSV, influenza, and COVID-19 vaccination programs. Four disease models estimated averted morbidity, mortality, and productivity losses. We evaluated current CDC recommendations and scenarios of varying eligibility and coverage. A complementary analysis estimated the net present value of 1 year's vaccination activity.
RESULTS: Under current age-based recommendations, vaccination prevents over 182 000 deaths and 2.5 million hospitalizations within 15 years. Society values these outcomes at 5-12 times the cost of delivering the programs. Including at-risk adults averts an additional 13 600 deaths. Restricting eligibility or coverage could increase vaccine-preventable hospitalizations by over 1 million, increasing healthcare costs by almost $50 billion; expanding eligibility and increasing coverage to 75% substantially improves societal welfare and could additionally avert over 100 000 deaths. One year's vaccination activity prevents ∼300 000 hospitalizations, and ∼18 500 deaths, generating $6-$12 in societal value per $1 spent.
CONCLUSIONS: Adult respiratory vaccination programs generate considerable societal returns. Increasing coverage and sustaining clear, evidence-based recommendations can unlock further health and economic gains.